Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised
Par un écrivain mystérieux
Description
![Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised](https://www.thelancet.com/cms/attachment/9dc017b1-83d8-4987-adb1-42bcac26aefc/gr1.gif)
Radiotherapy plus cisplatin or cetuximab in low-risk human
![Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised](https://ars.els-cdn.com/content/image/1-s2.0-S0959804921002185-gr1.jpg)
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin
![Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised](https://www.frontiersin.org/files/Articles/464084/fonc-09-00668-HTML/image_m/fonc-09-00668-t001.jpg)
Frontiers The Evolving Role of Taxanes in Combination With
![Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised](https://onlinelibrary.wiley.com/cms/asset/1430d3b6-c937-48ea-8a10-e182cbfa0c5c/mco2312-fig-0003-m.jpg)
A pilot study of camrelizumab with docetaxel and cisplatin for the
![Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41392-022-01297-0/MediaObjects/41392_2022_1297_Fig4_HTML.png)
Targeted therapy for head and neck cancer: signaling pathways and
![Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised](https://www.thelancet.com/cms/asset/a0142152-c603-4550-90a3-1fe57421a233/gr1.jpg)
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil
![Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised](https://ars.els-cdn.com/content/image/1-s2.0-S0959804921004214-gr3.jpg)
First-line treatment with chemotherapy plus cetuximab in Chinese
![Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised](https://media.springernature.com/lw367/springer-static/image/art%3A10.1007%2Fs12254-023-00901-5/MediaObjects/12254_2023_901_Fig1_HTML.png?as=jpg)
Current systemic treatment options and new developments in
![Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised](https://ars.els-cdn.com/content/image/1-s2.0-S0923753422047780-gr3.jpg)
Durvalumab with or without tremelimumab versus the EXTREME regimen
![Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised](https://pub.mdpi-res.com/biomedicines/biomedicines-11-02887/article_deploy/html/images/biomedicines-11-02887-g001-550.jpg?1698223297)
Biomedicines, Free Full-Text
![Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised](https://www.frontiersin.org/files/MyHome%20Article%20Library/714551/714551_Thumb_400.jpg)
Frontiers Weekly Paclitaxel, Carboplatin, and Cetuximab as First
![Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41392-022-01297-0/MediaObjects/41392_2022_1297_Fig6_HTML.png)
Targeted therapy for head and neck cancer: signaling pathways and
depuis
par adulte (le prix varie selon la taille du groupe)